Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How should COMET influence heart failure practice?

Kirkwood F Adams1

  • 1The University of North Carolina at Chapel Hill Heart Failure Program, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA. kfa@med.unc.edu

Current Heart Failure Reports
|July 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial.

Nature medicine·2025
Same author

Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction.

ESC heart failure·2024
Same author

Association of Depression Symptoms and Biomarkers of Risk on Clinical Outcomes in HFrEF.

medRxiv : the preprint server for health sciences·2023
Same author

The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.

Journal of cardiac failure·2023
Same author

Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.

JACC. Heart failure·2023
Same author

Circulating Angiokines Are Associated With Reverse Remodeling and Outcomes in Chronic Heart Failure.

Journal of cardiac failure·2023
Same journal

From Cardioprotection to Trial Design: Rethinking Cardiac Safety in Oncology.

Current heart failure reports·2026
Same journal

Acute and Chronic Myocarditis in Men and Women.

Current heart failure reports·2026
Same journal

Smart Technology, Fragile Hearts: Navigating AI's Challenges and Limitations in Heart Failure Management.

Current heart failure reports·2026
Same journal

Palliative Care in Advanced Heart Failure.

Current heart failure reports·2026
Same journal

The Evolving Utility of Artificial Intelligence-Based Tools for the Detection of Heart Failure and Cardiomyopathies: From Potential to Implementation.

Current heart failure reports·2026
Same journal

Emerging Artificial Intelligence Tools for the Screening of Structural and Valvular Heart Disease.

Current heart failure reports·2026
See all related articles

The Carvedilol or Metoprolol European Trial (COMET) found carvedilol superior to metoprolol for heart failure mortality benefits. This highlights the importance of using proven beta-blockers in heart failure treatment.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Clinical experience suggested similar mortality benefits for beta-blockers in heart failure.
  • The Carvedilol or Metoprolol European Trial (COMET) challenged this assumption.

Purpose of the Study:

  • To evaluate the comparative mortality benefits of carvedilol and immediate-release metoprolol in heart failure patients.
  • To investigate the reasons behind observed efficacy differences between beta-blockers.

Main Methods:

  • Analysis of data from the COMET trial comparing carvedilol and immediate-release metoprolol.
  • Examination of pharmacodynamic and hemodynamic data to assess beta-1 blockade levels.

Main Results:

  • Carvedilol demonstrated greater mortality benefits compared to immediate-release metoprolol in heart failure.

Related Experiment Videos

  • Unequal degrees of beta-1 blockade were suggested between the treatment groups.

    • Conclusions:

    • COMET results support using beta-blockers proven effective in large trials for heart failure.
    • Further research is needed to clarify benefits of selective vs. nonselective adrenergic blockade beyond beta-1 blockade.